Cargando…
Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients
Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978892/ https://www.ncbi.nlm.nih.gov/pubmed/29214504 http://dx.doi.org/10.1007/s10096-017-3157-7 |
_version_ | 1783327576916230144 |
---|---|
author | Reidenberg, Bruce E. Wanner, Christoph Polsky, Bruce Castanheira, Mariana Shelip, Alla Stalleicken, Dirk Pfaffle, Antony E. |
author_facet | Reidenberg, Bruce E. Wanner, Christoph Polsky, Bruce Castanheira, Mariana Shelip, Alla Stalleicken, Dirk Pfaffle, Antony E. |
author_sort | Reidenberg, Bruce E. |
collection | PubMed |
description | Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make this an appropriate target for applying a nonspecific antimicrobial therapeutic. Taurolidine hydrolyzes into two antimicrobial moieties, formaldehyde and methylene glycol, which react with microbial surfaces. Neutrolin® (taurolidine, heparin, calcium citrate) was recently introduced in Germany as an antimicrobial catheter lock solution. This postmarketing experience collected data on 201 patients at 20 centers from January 2014 through September 2016. Likely CRBSI was observed in 13 episodes in 47,118 days (0.2759 per 1000 days [0.1468, 0.4718]). Thrombosed catheter was observed in seven catheters in 47,118 days (0.1486 per 1000 days [0.0595, 0.3061]). No adverse drug reactions that led to the discontinuation of Neutrolin® use were reported. Two patients experienced occasional transient dysgeusia. Neutrolin®, when used in conjunction with guideline-based catheter care, showed reduction in the rate of both CRBSI and catheter thrombosis relative to recent historical controls. |
format | Online Article Text |
id | pubmed-5978892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-59788922018-06-21 Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients Reidenberg, Bruce E. Wanner, Christoph Polsky, Bruce Castanheira, Mariana Shelip, Alla Stalleicken, Dirk Pfaffle, Antony E. Eur J Clin Microbiol Infect Dis Original Article Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make this an appropriate target for applying a nonspecific antimicrobial therapeutic. Taurolidine hydrolyzes into two antimicrobial moieties, formaldehyde and methylene glycol, which react with microbial surfaces. Neutrolin® (taurolidine, heparin, calcium citrate) was recently introduced in Germany as an antimicrobial catheter lock solution. This postmarketing experience collected data on 201 patients at 20 centers from January 2014 through September 2016. Likely CRBSI was observed in 13 episodes in 47,118 days (0.2759 per 1000 days [0.1468, 0.4718]). Thrombosed catheter was observed in seven catheters in 47,118 days (0.1486 per 1000 days [0.0595, 0.3061]). No adverse drug reactions that led to the discontinuation of Neutrolin® use were reported. Two patients experienced occasional transient dysgeusia. Neutrolin®, when used in conjunction with guideline-based catheter care, showed reduction in the rate of both CRBSI and catheter thrombosis relative to recent historical controls. Springer Berlin Heidelberg 2017-12-06 2018 /pmc/articles/PMC5978892/ /pubmed/29214504 http://dx.doi.org/10.1007/s10096-017-3157-7 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Reidenberg, Bruce E. Wanner, Christoph Polsky, Bruce Castanheira, Mariana Shelip, Alla Stalleicken, Dirk Pfaffle, Antony E. Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients |
title | Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients |
title_full | Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients |
title_fullStr | Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients |
title_full_unstemmed | Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients |
title_short | Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients |
title_sort | postmarketing experience with neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978892/ https://www.ncbi.nlm.nih.gov/pubmed/29214504 http://dx.doi.org/10.1007/s10096-017-3157-7 |
work_keys_str_mv | AT reidenbergbrucee postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients AT wannerchristoph postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients AT polskybruce postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients AT castanheiramariana postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients AT shelipalla postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients AT stalleickendirk postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients AT pfaffleantonye postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients |